Oloa

Bromelain (BR) o se cysteine ​​protease faʻatasi ai ma aʻafiaga faʻalavelave i le faʻaogaina o le intestinal ma le mumū.Ae ui i lea, o ona aʻafiaga i le gaogao o le intestinal e tele lava ina le suʻesuʻeina.O le mea lea, na matou suʻesuʻeina ai le aʻafiaga o lenei vailaʻau faʻapipiʻi i luga o le intestinal contractility ma le felauaiga i mice.Contractility in vitro na iloiloina e ala i le faʻaosofiaina o le ileum vavae ese o le isumu, i totonu o le taele okeni, faʻatasi ai ma le acetylcholine, barium chloride, poʻo le eletise eletise.O le gaioi i vivo na fuaina e ala i le iloiloina o le tufaina atu o se fa'ailoga fa'amumū fa'ao'o tautala i luga o le tootoo la'ititi.Sa iloiloina foi le felauaiga i setete pathophysiologic e mafua mai i le suauu croton compound pro-inflammatory poʻo le sui o le diabetogenic streptozotocin.Bromelain faʻalavelave faʻalavelave faʻaosoina e eseese spasmogenic compounds ile ileum isumu ma le malosi tutusa.O le aʻafiaga o le antispasmodic na faʻaitiitia pe faʻafefe e le inhibitor enzyme proteolytic, gabexate (15 × 10 (-6) mol L (-1) ), protease-activated r eceptor-2 (PAR-2) antagonist, N (1) -3 -methylbutyryl-N(4) -6-aminohexanoyl-piperazine (10(-4) mol L(-1) ), phospholipase C (PLC) inhibitor, neomycin (3 × 10(-3) mol L(-1) ) , ma le phosphodiesterase 4 (PDE4) inhibitor, rolipram (10(-6) mol L(-1) ).I totonu o le vivo, o le BR e sili ona faʻalavelaveina le gaogao i tulaga pathophysiologic i se PAR-2-antagonist-maʻaleʻale auala.O matou faʻamatalaga e fautua mai ai o le BR faʻalavelaveina le gaogao o le intestinal - e sili atu i tulaga pathophysiologic - faʻatasi ai ma se masini e ono aofia ai le membrane PAR-2 ​​ma PLC ma PDE4 e pei o intracellular. faailoilo.Bromelain e mafai ona avea ma taʻitaʻia faʻapipiʻi mo le atinaʻeina o vailaʻau fou, e mafai ona faʻasaʻo le gaogao o le intestinal i le mumū ma le maʻisuka.